Top-Rated StocksTop-RatedNASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis $30.51 +1.23 (+4.20%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Immunovant Stock (NASDAQ:IMVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunovant alerts:Sign Up Key Stats Today's Range$29.53▼$30.6650-Day Range$26.71▼$34.0352-Week Range$24.67▼$45.58Volume761,856 shsAverage Volume1.13 million shsMarket Capitalization$4.46 billionP/E RatioN/ADividend YieldN/APrice Target$49.09Consensus RatingBuy Company OverviewImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Read More… CNBC’s ‘Prophet’ issues urgent Fed warning (Ad)"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview Immunovant Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks32nd Percentile Overall ScoreIMVT MarketRank™: Immunovant scored higher than 32% of companies evaluated by MarketBeat, and ranked 838th out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunovant has only been the subject of 4 research reports in the past 90 days.Read more about Immunovant's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($2.43) to ($2.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -16.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -16.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 7.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunovant's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.09% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 0.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.09% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 0.56%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.29 News SentimentImmunovant has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Immunovant this week, compared to 5 articles on an average week.Search Interest16 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $904,638.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunovant's insider trading history. Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Stock News HeadlinesZacks Research Comments on Immunovant, Inc.'s FY2026 Earnings (NASDAQ:IMVT)October 3 at 6:43 AM | americanbankingnews.comBuy Rating for Immunovant: A New Hope in Graves’ Disease TreatmentOctober 1, 2024 | markets.businessinsider.comNext opportunity for crypto millionsAs October unfolds and the effects of the Fed Pivot ripple through the market, this crypto could skyrocket. Want to know more?October 5, 2024 | Crypto 101 Media (Ad)Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?October 1, 2024 | finance.yahoo.comImmunovant's (IMVT) "Buy" Rating Reaffirmed at HC WainwrightOctober 1, 2024 | americanbankingnews.comImmunovant (NASDAQ:IMVT) Stock Price Up 2.7%September 27, 2024 | americanbankingnews.comBuy Rating Backed by Promising Batoclimab Results for Graves’ Disease TreatmentSeptember 25, 2024 | markets.businessinsider.comBuy Recommendation: Immunovant’s Novel Therapy Addresses Unmet Needs in Graves’ Disease TreatmentSeptember 25, 2024 | markets.businessinsider.comSee More Headlines IMVT Stock Analysis - Frequently Asked Questions How have IMVT shares performed this year? Immunovant's stock was trading at $42.13 at the start of the year. Since then, IMVT shares have decreased by 27.6% and is now trading at $30.51. View the best growth stocks for 2024 here. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.07. Who are Immunovant's major shareholders? Top institutional investors of Immunovant include SG Americas Securities LLC (0.01%). Insiders that own company stock include Sciences Ltd Roivant, Peter Salzmann, Julia G Butchko, Frank Torti, Eva Renee Barnett, Mark S Levine, William L Macias, Jay S Stout and Michael Geffner. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV) and Alibaba Group (BABA). Company Calendar Last Earnings8/06/2024Today10/05/2024Next Earnings (Estimated)11/14/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$49.09 High Stock Price Target$57.00 Low Stock Price Target$41.00 Potential Upside/Downside+60.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-259,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.07% Return on Assets-48.25% Debt Debt-to-Equity RatioN/A Current Ratio13.09 Quick Ratio13.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.25 per share Price / Book7.18Miscellaneous Outstanding Shares146,180,000Free Float137,555,000Market Cap$4.46 billion OptionableOptionable Beta0.67 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:IMVT) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.